Stock analysis, trade plans, and proprietary indicators by Trend Edge.
Trend Edge Setup Score
Trend Edge rates CLRB Bearish with a Setup Score of 16, net conviction 35, actionability 7. How the Setup Score works →
Total Setup Score
16
Directional Bias
Bearish
Net Conviction
35
Actionability
7 (in range)
Key signals behind this score
40wk Downtrend — falling+below (sma 3.15 vs px 2.82)
80wk Downtrend — falling+below (sma 5.32 vs px 2.82)
200wk Downtrend — falling+below (sma 43.27 vs px 2.82)
Funds Distributing — momZ +0.46 · 0.23→0.22
Seasonal Headwind — july med -8.4% (mag 3/3) · posClose 30.00% (rel 2/3) · n20 ×1 = 12.8
About Cellectar Biosciences Inc
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobu… Read full Trend Edge analysis →
Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
IPO Date: November 10, 2005
Headquarters: 100 Campus Drive, Florham Park, NJ, United States, 07932
Founder-Led: Yes — James V. Caruso (President, CEO & Director)
Key Metrics
Current Price
$2.82
Market Cap
$22.1M
Float
7.8M
Shares Outstanding
8.0M
Price/Sales (TTM)
348.47
vs. Analyst Target
+266.4% to analyst PT
Dividend Rate
None
Analyst Target Price
$10.33 (4 analysts)
Financial History
Annual Revenue & Earnings History
Year
Revenue
Net Income
Gross Profit
EBITDA
2020
N/A
-$15.1M
-$207,929
-$14.9M
2021
N/A
-$24.0M
-$227,636
-$24.0M
2022
N/A
-$28.6M
-$238,867
-$28.7M
2023
N/A
-$42.8M
-$192,375
-$42.6M
2024
N/A
-$44.6M
-$291,653
-$44.2M
2025
N/A
-$21.8M
-$213,597
-$21.6M
Recent Quarterly Revenue & Net Income
Quarter
Revenue
Net Income
Jun 2025
N/A
-$5.4M
Sep 2025
N/A
-$4.4M
Dec 2025
N/A
-$5.3M
Mar 2026
N/A
-$5.7M
Ownership & Float
Insider Ownership
2.1%
Institutional Ownership
16.6%
Short Float
0.7%
% of All Funds Holding
0.22%
Number of Funds Holding
18
Current Moving Averages
Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.
Timeframe
SMA
Value
Trend Context
Weekly
10-Week SMA
$2.83
Near-term / short-term trend
Weekly
40-Week SMA
$3.15
Medium-term trend
Weekly
80-Week SMA
$5.32
Cyclical trend (business cycle)
Weekly
200-Week SMA
$43.27
Secular trend (multi-year)
Monthly
10-Month SMA
$3.03
Near-term monthly trend
Monthly
20-Month SMA
$5.14
Medium-term monthly trend
Monthly
40-Month SMA
$39.79
Secular monthly trend
Volume Shelves — Support & Resistance
Trend Edge identifies volume shelves: price zones where historically elevated trading volume
creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative
volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.
Price Level
Type
Volume Ratio
Age
$2.70
support
7.59x
1 months ago
$5.50
resistance
1.57x
8 months ago
$46.00
resistance
4.62x
18 months ago
Historical Earnings Reactions (82 events)
Timeframe
Avg Return
Median
Win Rate
Best
Worst
Gap
0.18%
0.00%
42.68%
9.60%
-14.29%
1 Day
-0.21%
-0.59%
32.93%
11.43%
-12.31%
1 Week
-1.91%
-1.94%
32.93%
45.37%
-38.38%
2 Weeks
0.49%
-3.09%
35.37%
113.79%
-37.08%
1 Month
2.10%
-3.51%
38.27%
127.59%
-86.44%
Next earnings: August 13, 2026 (31 days away)
Seasonality & Day-of-Week Patterns
Monthly Seasonality
Month
Avg Return
Win Rate
Samples
Jan
4.9%
52.4%
21
Feb
-6.6%
52.4%
21
Mar
-3.2%
38.1%
21
Apr
0.6%
38.1%
21
May
1.1%
38.1%
21
Jun
-9.2%
28.6%
21
Jul
-11.0%
30.0%
20
Aug
-2.4%
35.0%
20
Sep
-2.8%
40.0%
20
Oct
-14.5%
10.0%
20
Nov
-8.5%
30.0%
20
Dec
8.9%
38.1%
21
Day-of-Week Tendencies
Day
Avg Return
Win Rate
Samples
Monday
-0.16%
37.2%
973
Tuesday
-0.07%
36.9%
1066
Wednesday
-0.33%
36.7%
1066
Thursday
-0.28%
36.7%
1045
Friday
0.46%
41.0%
1041
Top Institutional Holders
Institutional holder breakdown coming soon.
Total institutional ownership: 16.6%
Insider Transactions — Smart Summary
Total insider ownership: 2.1%
Founder-led management: James V. Caruso (President, CEO & Director)
Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Cellectar Biosciences Inc
(CLRB) powered by Claude Opus — Anthropic's most capable AI model.
The analysis covers five layers:
technical analysis (near-term, medium-term, cyclical, and secular trend, momentum,
volume shelf support and resistance, breakout and breakdown signals),
qualitative analysis (business model, competitive moat, sector dynamics),
insider sentiment (buy and sell signals from executive and director transactions),
share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and
fundamental analysis (valuation, revenue growth, profit margin, earnings quality).
AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit,
stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward.
Whether you are building a long position, initiating a short, or looking for a reversal setup,
AI Consult identifies the highest-probability signal from the current trend.